their condition, to rate how badly they are affected, and, finally, to weight the relative importance of potential improvements in these areas. Although the MYMOP is promoted as a patient centred measure, it imposes three professionally derived dimensions on the patient and fails to take account of the relative importance that he or she attaches to these disparate domains. It is unclear if the patient centredness of the original measure has been compromised.

An instrument that is valid must be reliable, but validity is a relative concept. The methods used by researchers in assessing validity are crude, particularly when applied to quality of life measures. The fact that the MYMOP seems to be "fairly" valid does not mean that it is precise enough to detect real differences in an individual over repeated administrations. It may well satisfy the reliability requirements for assessments of individual patients, but this needs to be shown.

In summary, we would recommend the following methods to anyone wishing to develop the MYMOP approach: in depth interviews with patients who have completed the instrument to assess qualitatively its face and content validity; a content analysis of the symptoms and activities that patients include in their MYMOP; reliability testing; and correlation of scores obtained with the MYMOP with those obtained with a quality of life measure such as the patient generated index.

DANNY RUTA
Senior lecturer

Department of Epidemiology and Public Health,
University of Dundee,
Dundee DD1 9NL

ANDREW GARRATT
Research fellow

Department of Health Sciences,
University of York,
York

- 1 Paterson C. Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey. *BMJ* 1996;312:1016-20. (20 April.)
- 2 Ruta DA, Garratt AM, Leng M, Russell IT, Macdonald LM. A new approach to the measurement of quality of life: the patient-generated index. *Med Care* 1994;32:1109-26.
- 3 Calman KC. Quality of life in cancer patients—a hypothesis. *J Med Ethics* 1984;10:124.

Author's reply

EDITOR,—Crispin Jenkinson's sweeping dismissal of patients' symptoms is perhaps explained by his seclusion in an academic health services research unit. The "measure yourself medical outcome profile" (MYMOP) is designed as a tool for primary care, and my experience as a general practitioner shows that symptoms are patients' expressions of their problems. Because the MYMOP allows patients to express those symptoms in their own words it is not, as Jenkinson suggests, a "medicalised approach," which is why it is applicable to complementary as well as general medical care. Examples of patients' chosen symptoms are "a burning sickness" and "a feeling of water gushing over the head." The MYMOP does not aspire to measure a person's health status or total quality of life; it aspires simply to measure improvement or deterioration in a particular aspect for which the patient has sought help. The fact that Jenkinson also dismisses the evidence gained from interviews is surprising, as the discovery that "practitioners gained new insights into the patient's view of the problem" was, for me, one of the most exciting aspects of the study.

W R Primrose and colleagues raise the important question of rates of completion of the forms among older age groups. My data suggest that people aged over 65 have difficulty with the short form health profile, the SF-36. Of the 265 patients in the study, 50 were aged over 65 (the mean age of this group being 73). The response

rate in this group was 84% at four weeks, compared with 73% for the whole sample. Out of 126 MYMOP forms completed by this group, only three (2.4%) were incomplete, compared with 7% for the whole sample. Of the 91 SF-36 forms completed by this group, however, 25 (27%) were incomplete to such an extent that they could not be fully scored in accordance with the authors' guidance notes; this compares with a 14% incompleteness rate for the SF-36 for the whole sample.

I am grateful for Danny Ruta's comments and suggestions for further development of the MYMOP, several of which I mentioned in my paper. A study entailing in depth interviews with patients and correlations between the MYMOP and the general wellbeing index is due to start this winter.

CHARLOTTE PATERSON
General practitioner

Warwick House Medical Centre,
Taunton,
Somerset TA1 2YJ

Global eradication of polio by 2000 is not a realistic goal

EDITOR,—While the eradication of polio is progressing well in many countries that are politically stable, such as India, this is not the case in areas of conflict. During an outbreak of polio in wartorn Chechnya in 1995, 143 confirmed cases of paralytic polio occurred (fig 1). Oral polio vaccine is heat labile and requires a good cold chain. As in many other areas of conflict, the cold chain had been destroyed. The attempts of Merlin (Medical Emergency Relief International), together with the local authorities, to rebuild the cold chain and facilitate mass vaccination have been only partially successful owing to the continuing fighting and poor access. The percentage of children in the Russian Federation who received diphtheria, tetanus, and pertussis vaccine fell from over 90% in 1980 to less than 43% in 1992, which resulted in a massive outbreak of diphtheria.¹ This outbreak of polio in Chechnya is a real threat to the rest of the Russian Federation and the newly independent states of the Caucasus. Russia is rightly starting a mass polio vaccination campaign, which will run in addition to its well established mass diphtheria campaign.

Fig 1—Cases of poliomyelitis in Chechnya in 1995 by week of onset (n=143)

Eradication is defined as no cases of paralytic poliomyelitis due to wild poliovirus and the

absence of environmental circulation of wild poliovirus. I think that we will get there in the end, but, sadly, the areas of conflict in the world will ensure that small numbers of cases will persist well beyond 2000.

JOHN HOWARTH
Medical director

Merlin (Medical Emergency Relief International),
1A Rede Place,
London W2 4TU

- 1 Dittmann S. The diphtheria situation in the newly independent states and the WHO/Unicef strategy to control diphtheria. Geneva: World Health Organisation, 1995.

Diagnoses of melanoma need further investigation

EDITOR,—Rona M MacKie and David J Hole seem surprised that melanoma is diagnosed more commonly in affluent people yet the outcome is better than in less affluent people,¹ but that was only to be expected, since there is no evidence that the flat lesions culled after programmes to increase awareness of melanomas are malignant.^{2,4} People have been frightened into going to their doctors with benign moles, seborrhoeic warts, and minor skin cancers or precancers; these have blocked clinics and may have delayed the treatment of killer melanomas.

The muddle started in the early 1980s when, for reasons more social than professional, moles were removed even when thought to be benign. Histological reporting evolved in sympathy, edging from "benign" to "benign with suspicious features" to "? malignant" to "frankly malignant." There was no clinical evidence of malign activity, and because the lesions were excised their natural course could not be determined. As more moles were excised more unexpected malignancies were reported, and the more they were reported the more they were excised; the practice grew on the basis of (comforting) consensus, not evidence. The (always dubious) practice of removal "just to be sure" had grown out of control through programmes to increase awareness of melanoma; these were ill advised, because there are no usefully predictive features of early melanoma—enlargement, darkening, itching, and bleeding do not discriminate. Affluent people always head the social queue, and it is no surprise that they turned up to have their benign lesions removed and to swell the figures for a good outcome.

Histological prediction relies on previous clinicopathological correlation. Histologically, a juvenile melanoma looks as wild as Rambo rampant and a simple mole may look malignant after a shave excision, but their benign clinical progress taught us that they are tame. Clinical knowledge (now, alas, lost) similarly told us to ignore the flat lesions now diagnosed as malignant. Histological interpretation must follow from the natural course, not vice versa; we need to know whether we have inappropriate histological criteria or, more excitingly, self healing, or only locally malignant, melanomas.

MacKie and Hole's findings point to the benignity of lesions now being diagnosed as malignant (the authors' attempt to use the thickness of the lesion rather than intrinsic aggression to relate mortality to social status is unconvincing: it confounds biological assumption with a statistical presumption). Their findings make it all the more urgent that the problem is now fully investigated. As we have learnt again from the beef crisis, good health policy can come only from good science.

SAM SHUSTER
Emeritus professor of dermatology

University of Newcastle upon Tyne,
Newcastle upon Tyne NE2 4BW

- 1 MacKie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant